UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Thiazolidinediones and the Risk of Lung, Prostate, and Colon Cancer in Patients With Diabetes

Journal of clinical oncology, 2007-04, Vol.25 (12), p.1476-1481

2007

Volltextzugriff (PDF)

Absolute lymphocyte count (ALC) as predictor of Pneumocystis Jiroveci Pneumonia (PCP) infection in patients on immune checkpoint inhibitors (ICPi)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14255-e14255

2019

Volltextzugriff (PDF)

The effect of exposure to thiazolidinediones on the development of head-and-neck cancer in patients with diabetes mellitus

Translational research in oral oncology, 2017-01, Vol.2

2017

Volltextzugriff (PDF)

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors

Journal for immunotherapy of cancer, 2024-09, Vol.12 (9), p.e009128

2024

Volltextzugriff (PDF)

Gender differences in relative survival among patients with primary peritoneal carcinoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e13092-e13092

2019

Volltextzugriff (PDF)

Cisplatin and gemcitabine versus carboplatin and gemcitabine in metastatic bladder cancer: Survival analysis of veterans' health care data

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e16023-e16023

2017

Volltextzugriff (PDF)

Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia

Blood, 2014-11, Vol.124 (23), p.3503-3505

2014

Volltextzugriff (PDF)

C-reactive protein (CRP) as a predictive biomarker in lung cancer patients receiving immune checkpoint inhibitors (ICI)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21645-e21645

2020

Volltextzugriff (PDF)

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

Nature medicine, 2020-10, Vol.26 (10), p.1564-1568

2020

Volltextzugriff (PDF)

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11516-11516

2023

Volltextzugriff (PDF)

Effect of hepatitis C virus (HCV) on the outcome of hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e15634-e15634

2016

Volltextzugriff (PDF)

Impact of performance status (PS) on oncologists' decision to administer chemotherapy (CTX) and overall survival (OS)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e17580-e17580

2014

Volltextzugriff (PDF)

Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006

Journal of clinical oncology, 2006-10, Vol.24 (28), p.e48-e48

2006

Volltextzugriff (PDF)

Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer

American journal of clinical oncology, 2018-07, Vol.41 (7), p.638-642

2018

Volltextzugriff (PDF)

Comparison of initial diagnosis and treatment for Hepatocellular Carcinoma (HCC) between Veterans Affairs (VA) and SEER populations

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15123-e15123

2015

Volltextzugriff (PDF)

Incidence of peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin alone vs. radiation therapy and oxaliplatin

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e18281-e18281

2017

Volltextzugriff (PDF)

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

Investigational new drugs, 2012-08, Vol.30 (4), p.1646-1651

2012

Volltextzugriff (PDF)

Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic Hepatocellular Carcinoma

American journal of clinical oncology, 2013-06, Vol.36 (3), p.254-257

2013

Volltextzugriff (PDF)

Impact of race on outcome of stage II colon cancer subjects not receiving adjuvant therapy

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.6574-6574

2014

Volltextzugriff (PDF)

Abstract CT013: SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT013-CT013

2020

Volltextzugriff (PDF)

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10039-10039

2020

Volltextzugriff (PDF)

Oral (O) versus intravenous (IV) etoposide and platinum in the treatment of extensive-stage small cell lung cancer (SCLC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7597-7597

2013

Volltextzugriff (PDF)

A Phasephase II Basketbasket Trialtrial of Dualdual Anti-CTLA-4 and Anti-PD-1 Blockadeblockade in Rarerare Tumorstumors (DART) SWOG S1609: ThePhase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors

Journal for immunotherapy of cancer, 2024-09, Vol.12 (9)

2024

Volltextzugriff (PDF)

Autoimmune Thrombocytopenic Purpura and Anti-HCV Therapy: An Unusual Association: 1071

The American journal of gastroenterology, 2012-10, Vol.107, p.S433

2012

Volltextzugriff (PDF)

Irinotecan/thalidomide in metastatic colorectal cancer

Oncology (Williston Park, N.Y.), 2002-04, Vol.16 (4 Suppl 3), p.23-26

Govindarajan, Rangaswamy

2002

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(20)
Science & Technology
(19)
Life Sciences & Biomedicine
(17)
Oncology
(14)
Middle Aged
(13)
Aged
(11)
Female
(11)
Male
(11)
Adult
(9)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Tumors
(7)
Patients
(6)
Prognosis
(6)
Aged, 80 And Over
(5)
Cancer Research
(4)
Pharmacology. Drug Treatments
(4)
Registries
(4)
Treatment Outcome
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Thiazolidinediones and the Risk of Lung, Prostate, and Colon Cancer in Patients With Diabetes

Absolute lymphocyte count (ALC) as predictor of Pneumocystis Jiroveci Pneumonia (PCP) infection in patients on immune checkpoint inhibitors (ICPi)

The effect of exposure to thiazolidinediones on the development of head-and-neck cancer in patients with diabetes mellitus

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors

Gender differences in relative survival among patients with primary peritoneal carcinoma

Cisplatin and gemcitabine versus carboplatin and gemcitabine in metastatic bladder cancer: Survival analysis of veterans' health care data

Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia

C-reactive protein (CRP) as a predictive biomarker in lung cancer patients receiving immune checkpoint inhibitors (ICI)

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27)

Effect of hepatitis C virus (HCV) on the outcome of hepatocellular carcinoma (HCC)

Impact of performance status (PS) on oncologists' decision to administer chemotherapy (CTX) and overall survival (OS)

Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006

Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer

Comparison of initial diagnosis and treatment for Hepatocellular Carcinoma (HCC) between Veterans Affairs (VA) and SEER populations

Incidence of peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin alone vs. radiation therapy and oxaliplatin

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic Hepatocellular Carcinoma

Impact of race on outcome of stage II colon cancer subjects not receiving adjuvant therapy

Abstract CT013: SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320

Oral (O) versus intravenous (IV) etoposide and platinum in the treatment of extensive-stage small cell lung cancer (SCLC)

A Phasephase II Basketbasket Trialtrial of Dualdual Anti-CTLA-4 and Anti-PD-1 Blockadeblockade in Rarerare Tumorstumors (DART) SWOG S1609: ThePhase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors

Autoimmune Thrombocytopenic Purpura and Anti-HCV Therapy: An Unusual Association: 1071

Irinotecan/thalidomide in metastatic colorectal cancer

Suchergebnisse filtern